Clinically speaking, cancer is characterized by unchecked cell proliferation and a gene-level deficiency in regulating cell division and tissue growth. According to a alarming WHO statistic, breast cancer has overtaken ovarian cancer as the second most frequent malignancy in women. In 2020, there were more than 2.3 million new cases and 6,85,000 fatalities. The current situation, which includes more adverse reactions to conventional chemotherapy and repeated desensitization of tumor cells by exposure to radiation, prompt researchers in the field of cancer biology to look into potential alternatives to current treatments that might not have as many side effects. Gandhaga Rasayanam (GR), a siddha formulated medication, recommended for treating leucoderma, piles, psoriasis, skin infections as per Siddha text “Siddha Vaithiya Thirattu” present to possess anti cancer properties. Using the MCF-7 breast cancer cell line and an in-vitro MTT assay, the current study examined the assessment of cell viability and cytotoxicity of this unique formulation

Siddha medicine, Gandhaga Rasayanam, Breast cancer, Anti-cancer, MTT assay

This in vitro study confirms that Fundamental anticancer properties of GR on dose dependent, pave the way for in vivo studies and support the benefits of gandhaga rasayanam, as an evidence-based alternative to breast cancer treatment

Pooja M., Shamsiya L., Suresh S. and Balagurusamy K. (2023). In-Vitro Cytotoxicity of Gandhaga Rasayanam (GR) on Human Breast Cancer (MCF-7) Cells. Biological Forum – An International Journal, 15(3a): 46-54